Navigation Links
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Date:3/1/2010

tute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

SOURCE Anadys Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.anadyspharma.com

'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... , HAYWARD, Calif., Nov. 17 ... today announced that its readerless CD4 point-of-care (POC) technology ... as the best-performing POC test method for measuring CD4 T-cell ... only remaining POC product being supported by the CD4 Initiative. ...
... , BEDFORD, Mass., Nov. 16 Hologic, ... a leading developer, manufacturer and supplier of premium diagnostics, ... the healthcare needs of women, is participating in the ... November 15-19, 2009 in Orlando, Florida, and will feature ...
Cached Medicine Technology:Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries 2Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries 3Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 2Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 3Hologic to Feature Adiana(R) Permanent Contraception System at AAGL 2009 4
(Date:7/30/2015)... ... July 30, 2015 , ... The Beryl Institute ... Program. In partnership with Patient Experience Institute, these offerings reinforce the commitment to ... front lines and throughout the experience movement, and provide information and research to ...
(Date:7/30/2015)... Melbourne, FL (PRWEB) , ... July 30, 2015 , ... ... Central Florida’s (UCF) College of Medicine as Assistant Professor of Plastic Surgery. This ... years, Dr. Clevens has worked closely with the university, developing a strong presence and ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... ‘Mary Jo Lawyer-Spano Mesothelioma Patient Registry Act of 2015’. The bill was introduced ... (R-NY), Peter King (R-NY), Betty McCollum (D-MN), Joe Kennedy (D-MA), and Leonard Lance ...
(Date:7/30/2015)... ... July 30, 2015 , ... Using the latest online digital ... people more effective ways to prevent and manage major depression. , “Suicide is 100% ... so people fall through the cracks and die needlessly everyday,” says Walker. “I’m out ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... Partners All-Star at the annual All-Stars Summit. Google Partners is the platform for ... may receive the full support and tools necessary to run successful search marketing ...
Breaking Medicine News(10 mins):Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Bill to Create Patient Registry for Deadly Cancer Introduced in Congress 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 2Health News:Happiness Expert Develops Pioneering Online Tools for Sufferers of Major Depression, and Who may be Suicidal 3Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2
... (BIDMC) has been awarded a grant from the National ... the National Institutes of Health, to lead a Consortium ... grant totals $36 million. BIDMC Chief of Vaccine ... Medicine at Harvard Medical School, will co-lead the new ...
... Bristol-Myers Squibb Company announced results from a long-term, ... (ARV)-experienced patients (336 female and 958 male) from ... at the Sixth International AIDS Society Conference on ... In a gender-specific sub-analysis, boosted REYATAZ (atazanavir sulphate) ...
... (HealthDay News) -- Personality traits may play key roles in ... from the U.S. National Institute on Aging found that people ... to be overweight. And those who are highly neurotic and ... many ups and downs. "Individuals with this constellation of ...
... , TUESDAY, July 19 (HealthDay News) -- People who ... able to decide what they like or don,t like more ... the study, published in the Journal of Consumer Research ... either likable subjects (puppies) or unpleasant things (diseased feet) or ...
... falling into poverty is an increasingly common experience among ... jointly by the Heller School,s Institute on Assets and ... organization Demos. And, researchers say, the situation could ... The report, "From Bad to Worse: Senior Economic ...
... large waist size is unhealthy for anyone, but for kidney disease ... of dying, a new study reports. The study doesn,t ... it suggests there may be a link. In their ... aged 45 and older who had kidney disease. The patients were ...
Cached Medicine News:Health News:In the real life setting, boosted REYATAZ proves as effective in women living with HIV as men 2Health News:Does Your Personality Dictate Whether You'll Be Overweight? 2Health News:Happy Shoppers More Decisive When Purchasing 2Health News:New report shows seniors' economic security falling 2Health News:As Waistline Expands, So Does Death Risk for Kidney Patients 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: